BI's Pradaxa presages comparator conundrum in Australia, warns industry
This article was originally published in Scrip
Executive Summary
The slow, and so far incomplete, journey to reimbursement for Boehringer Ingelheim's anti-coagulant Pradaxa (dabigatran) in Australia could foreshadow increasing problems for manufacturers that must justify the cost of their new innovative medicines when compared to older, cheaper drugs, warned Dr Brendan Shaw, chief executive of Medicines Australia, at a conference on the future of the PBS.